GlassScriptPhysician profile
Katherine J Anderson
NPI 1841459187
$1,635.46
in general payments reported to CMS, 2019-2025
26 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $17.30 · 2021: $13.64 · 2023: $536 · 2024: $473 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,472.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $299.89 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Novo Nordisk INC | $227.64 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $171.51 | 2023-2025 | |
| Exact Sciences Corporation | $146.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $126.14 | 2023-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $99.26 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $82.33 | 2020-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astellas Pharma US INC | $68.56 | 2023-2024 | Veozah |
| Hologic Sales and Service, LLC | $37.92 | 2019-2024 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $37.28 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.88 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $33.57 | 2025 | Capvaxive, Gardasil 9 |
| Seqirus USA INC | $32.74 | 2019-2025 | Flucelvax, Fluad |
| Insulet Corporation | $24.63 | 2019 | |
| Atricure, INC. | $22.22 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $21.58 | 2019 | |
| Gilead Sciences, INC. | $20.88 | 2024 | |
| Janssen Pharmaceuticals, INC | $19.67 | 2023 | Xarelto |
| Amryt Pharma Holdings LTD | $19.01 | 2023 | Mycapssa |
| Dynavax Technologies Corporation | $18.65 | 2023 | Heplisav-B |
| Astrazeneca Pharmaceuticals LP | $16.70 | 2025 | Airsupra |
| Idorsia Pharmaceuticals US INC | $16.55 | 2023 | Quviviq |
| Biotronik INC. | $14.91 | 2019 | |
| Ibsa Pharma INC. | $14.32 | 2023 | Tirosint, Licart |
| Novartis Pharmaceuticals Corporation | $14.11 | 2024 | |
| Inspire Medical Systems, INC. | $13.99 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.